The authors of the aforementioned article would like to make revisions to the labels in Figure 1 as shown below. The article has been corrected online.
Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting
Share
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Select a Section…
1
Article
2
Further Resources
Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Chemotherapy-induced myelosuppression has long been considered a toxicity that limits the dose of cytotoxic agents, which contributes to significant morbidity and mortality.1 Sub-optimal dose intensity may decrease the efficacy of therapy, thereby compromising progression-free survival (PFS) and overall survival (OS) benefits.2 Chemotherapy-induced myelosuppression is often managed with granulocyte-colony stimulating factors (G-CSFs) and erythropoiesis-stimulating agents (ESAs) […]
Mark CompleteCompleted
BookmarkBookmarked
Chemotherapy-induced myelosuppression has long been considered a toxicity that limits the dose of cytotoxic agents, which contributes to significant morbidity and mortality.1 Sub-optimal dose intensity may decrease the efficacy of therapy, thereby compromising progression-free survival (PFS) and overall survival (OS) ...
Mark CompleteCompleted
BookmarkBookmarked
Welcome to the latest edition of touchREVIEWS in Oncology & Haematology. Despite the success of the human papillomavirus vaccination programme, cervical cancer remains one of the most common cancers in women, and advanced disease carries a poor prognosis. Lebreton et ...
Mark CompleteCompleted
BookmarkBookmarked
Welcome to the winter edition of touchREVIEWS in Oncology & Haematology. Despite the continued impact of the COVID-19 pandemic on cancer care, 2021 has seen important advances in many areas of oncology, which is reflected in our diverse range of articles. ...
Mark CompleteCompleted
BookmarkBookmarked
Welcome to the inaugral issue of touchREVIEWS in Oncology & Haematology (formerly Oncology & Hematology Review [US]), which aims to summarize the latest clinical data and provide practical advice to help busy physicians in their daily practice. As co-editors-in-chief of ...
Mark CompleteCompleted
BookmarkBookmarked
Cancer is a growing problem that demands the best from all sectors of the global health workforce.1Â Cancer nurses make up the largest proportion of this workforce and, as well as being responsible for direct care delivery, also aim to ...
Mark CompleteCompleted
BookmarkBookmarked
Biosimilars, which are copies of patent-expired large-molecule biologic drugs (Table 1),1–8 offer the same rationale as generic drugs. They can give patients, hospitals and healthcare systems the opportunity to expand patient access to care and offer potential budget savings to reinvest (...
Mark CompleteCompleted
BookmarkBookmarked
Forty percent of Americans will be diagnosed with cancer in their lifetimes.1 Due to continued advances in cancer detection and treatment, there are an unprecedented number of cancer survivors. In fact, the 5-year survival rate for all cancers has increased ...
Mark CompleteCompleted
BookmarkBookmarked
Despite the increasing availability of precision medicine and the recent introduction of immune checkpoint inhibitors in the treatment of many tumours, chemotherapy remains the standard of care for most patients with cancer. Chemotherapy-induced nausea and vomiting (CINV) is highly prevalent ...
Mark CompleteCompleted
BookmarkBookmarked
Dear Colleagues, European Oncology & Haematology is now accepting submissions to the Summer and Winter 2018 editions. European Oncology & Haematology aims to publish topical articles, which are chosen for their evaluation of current practices and research that directly affect practitioners ...
Mark CompleteCompleted
BookmarkBookmarked
Dear Colleagues Oncology & Hematology Review (US) is now accepting submissions to the Spring and Fall 2018 editions. Oncology & Hematology Review (US) aims to provide practicing oncologists and hematologists with concise and timely articles that provide practical advice relevant to ...
Mark CompleteCompleted
BookmarkBookmarked
The estimated incidence of cancer increased by almost one third across Europe between 1995 and 2012, and this growth is predicted to continue.1,2 Compared with other diseases and disabilities, the lost years of life and productivity resulting from cancer represent a heavy ...
Mark CompleteCompleted
BookmarkBookmarked
Innovation in healthcare is highly beneficial from a patient perspective; however, the introduction of new drugs, often at high cost, is placing increasing pressure on many healthcare systems.1 As a result, these systems are facing a growing crisis of affordability, ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
